Candesartan, a blood-pressure drug, decreased the incidence of retinopathy in patients with Type 1 diabetes by 18% and lowered progression of the eye disorder by 35%, U.K. researchers reported. The findings add to evidence of the potential of the drug -- sold by AstraZeneca and Takeda Pharmaceutical as Atacand -- to reduce or prevent diabetic retinopathy.

Full Story:

Related Summaries